The plausible mechanisms of tramadol for treatment of COVID-19

El-Ashmawy, Nahla E.; Lashin, Abdel-Halim A.; Okasha, Kamal; Kamer, Amal M. Abo; Mostafa, Tarek; El‐Aasr, Mona; Goda, Ahmed E.; Haggag, Yusuf A.; Tawfik, Haytham O.; Abo-Saif, Mariam A.

doi:10.1016/j.mehy.2020.110468

Cited by 18 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of our study con rm this observation. The elderly usually take a lot of drugs (for chronic disorders typical for this population: pain, cardiovascular diseases, CNS (central nervous system) disorders, diabetes), some of which have an anti-in ammatory effect [22][23][24][25][26]. Such ongoing pharmacotherapy may in uence the risk of most common adverse effects associated with in ammation (pain, fever).…”

Section: Discussionmentioning

confidence: 99%

Safety of Pfizer-BioNTech COVID-19 mRNA Vaccine in the Elderly

Korzeniowska

Cieślewicz

Grabańska-Martyńska

et al. 2021

Preprint

View full text Add to dashboard Cite

Background. COVID-19 is an infectious viral disease that has affected more than 234 million people and has caused almost 4.8 million deaths worldwide. A patient's age is the most important factor influencing the risk of severe course of the disease. The elderly usually suffer from many ailments, and therefore, polypharmacy is a common phenomenon among them. Our paper presents the initial results of the analysis of adverse effects in the group of older people in the context of participants' pharmacotherapy. Methods. The information concerning post-vaccination adverse effects, COVID-19 in the past and current pharmacotherapy was collected from 200 people aged 60 years or older. Statistical analysis was performed using StatSoft Statistica 13.1 software. Results. Twenty-three participants reported adverse effects after vaccination. Statistical analysis of groups with and without adverse effects revealed significant differences in age, cardiovascular drugs, neurological and psychiatric drugs, analgesics, gastrointestinal drugs, supplements, and vitamins. Conclusions. Obtained results suggest the need to study the potential effect of ongoing pharmacotherapy on the safety and effectiveness of vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety of Pfizer-BioNTech COVID-19 mRNA Vaccine in the Elderly

Korzeniowska

Cieślewicz

Grabańska-Martyńska

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Hatékony fájdalomcsillapító, köhögéscsillapító, antipszichotikus hatása segítség a COVID-19-cel összefüggő organikus pszichoszindróma ellensúlyozásában. A tramadol baktericid hatású, például a Pseudomonas aeruginosával szemben, mely gyakori a kritikus állapotú COVID-19-betegekben [45].…”

Section: Röviden Néhány Opioidrólunclassified

Fájdalomtünetek és a fájdalomcsillapítás lehetőségei SARS-CoV-2-környezetben

Almási

2021

View full text Add to dashboard Cite

Összefoglaló. Az új koronavírusként megismert SARS-CoV-2-fertőzés legsúlyosabb szövődményeként a gyulladásos folyamatok jelátvivő molekuláinak elszabadulása – az ún. citokinvihar – kritikus légzési elégtelenséggel társuló akut respirációs diszfunkciós szindrómát vagy többszervi gyulladásos szindrómát okoz. Mostanáig igazolódott, hogy a fertőzések legnagyobb részben tünetmentesen vagy enyhe tünetekkel zajlanak. A betegség minden szakaszában előfordulhat enyhe vagy középsúlyos, ritkábban intenzív fájdalom, melyek enyhítésére számos fájdalomcsillapítási lehetőség áll rendelkezésre. A pandémia kezdete óta foglalkoznunk kell a tünetek enyhítésével, akár infektológiai osztályon, akár műtéti ellátás alkalmával. A betegek hazaengedését követően figyelmet kell fordítanunk az intenzív osztályos ellátás utáni és a COVID–19-et követő tünetek és fájdalmak értékelésére. Időszerű átfogó összefoglalónkban hangsúlyozzuk a különböző fájdalomcsillapítók szerepét a COVID–19-fertőzéssel összefüggő fájdalommal járó folyamatokban. Orv Hetil. 2021; 162(38): 1511–1519. Summary. As the most severe consequence of the new coronavirus SARS-CoV-2 infection, the cytokine storm – caused by the liberalization of several inflammatory mediators – engenders critical respiratory dysfunction syndrome or multisystem inflammatory syndrome. The most proportion of infections has proven symptomless or with very mild signs of disease so far. Mild, moderate, or rarely intense pain can occur in every phase of the disease, for the treatment of which more than a few analgesic possibilities are readily available. From the start of the pandemic, we have been concerning to ameliorate the symptoms, in either the department of infectology, or operating suites. The post-intensive care pain and post-COVID symptoms should be evaluated and treated after discharge. In this timely and comprehensive article, the role and importance of different analgesics are articulated regarding the COVID-associated painful conditions. Orv Hetil. 2021; 162(38): 1511–1519.

show abstract

“… 11 The therapeutic possibility for opioids in the treatment of COVID-19 has been identified including tramadol, given its anti-inflammatory, antioxidant, analgesic and antitussive effects. 12 , 13 Inhibition of the interaction of SARS-CoV-2 with ACE-2 by morphine and codeine has been identified as a therapeutic strategy for COVID-19. 14 Other in vitro studies included naloxone and naltrexone among drugs that could be repurposed for treatment of COVID-19.…”

mentioning

confidence: 99%

“… Opioids have drug-specific and varied systemic immunomodulatory effects that may influence the response to the virus. 3 , 4 , 11 , 13 3. Opioids have antitussive properties that could attenuate respiratory symptoms in COVID-19 patients such as shortness of breath and cough 1 4.…”

mentioning

confidence: 99%